

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A5C462C387FCEN.html>

Date: October 2022

Pages: 106

Price: US\$ 2,000.00 (Single User License)

ID: A5C462C387FCEN

Abstracts

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with

analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 2, 14, 19, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Anaplastic Astrocytoma - Overview

Anaplastic Astrocytoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaplastic Astrocytoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaplastic Astrocytoma - Companies Involved in Therapeutics Development

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Aettis Inc

AngioChem Inc

Apexigen Inc

Bayer AG

Berg LLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Candel Therapeutics Inc

CDG Therapeutics Inc

Cellix Bio Pvt Ltd

Chimerix Inc

Cothra Bioscience Pty Ltd

Curis Inc

Everfront Biotech Inc

Fore Biotherapeutics Inc

Geneos Therapeutics Inc

Ipsen SA

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Merck KGaA
MimiVax LLC
Mustang Bio Inc
Nascent Biotech Inc
Novartis AG
OncoSynergy Inc
Orbus Therapeutics Inc
Orphelia Pharma SAS
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
TheraBiologics Inc
Wayshine Biopharma Inc
Wuhan Binhui Biotechnology Co Ltd
Anaplastic Astrocytoma - Drug Profiles
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
aglatimagene besadenovec - Drug Profile
Product Description
Mechanism Of Action
BAY-1436032 - Drug Profile
Product Description
Mechanism Of Action
BAY-2666605 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
CLXONC-643 - Drug Profile
Product Description
Mechanism Of Action

dabrafenib mesylate - Drug Profile

Product Description

Mechanism Of Action

eflornithine - Drug Profile

Product Description

Mechanism Of Action

fimepinostat - Drug Profile

Product Description

Mechanism Of Action

FORE-8394 - Drug Profile

Product Description

Mechanism Of Action

futibatinib - Drug Profile

Product Description

Mechanism Of Action

G-207 - Drug Profile

Product Description

Mechanism Of Action

GENPV-001 - Drug Profile

Product Description

Mechanism Of Action

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

M-032 - Drug Profile

Product Description

Mechanism Of Action

MB-108 - Drug Profile

Product Description

Mechanism Of Action

MB-110 - Drug Profile

Product Description

Mechanism Of Action

OH-2 - Drug Profile

Product Description

Mechanism Of Action

ON-01 - Drug Profile

Product Description

Mechanism Of Action

ONC-206 - Drug Profile

Product Description

Mechanism Of Action

OS-2966 - Drug Profile

Product Description

Mechanism Of Action

P-28 - Drug Profile

Product Description

Mechanism Of Action

paclitaxel trevatide - Drug Profile

Product Description

Mechanism Of Action

palbociclib - Drug Profile

Product Description

Mechanism Of Action

paxalisib - Drug Profile

Product Description

Mechanism Of Action

pritumumab - Drug Profile

Product Description

Mechanism Of Action

regorafenib - Drug Profile

Product Description

Mechanism Of Action

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

selinexor - Drug Profile

Product Description

Mechanism Of Action

SL-701 - Drug Profile

Product Description

Mechanism Of Action

sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

sotigalimab - Drug Profile

Product Description

Mechanism Of Action

SurVaxM - Drug Profile

Product Description

Mechanism Of Action

TBX.OncV NSC - Drug Profile

Product Description

Mechanism Of Action

telaglenastat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

temozolomide - Drug Profile

Product Description

Mechanism Of Action

tepotinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

trotabresib - Drug Profile

Product Description

Mechanism Of Action

ubidecarenone - Drug Profile

Product Description

Mechanism Of Action

unesbulin - Drug Profile

Product Description

Mechanism Of Action

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

WSD-0922 - Drug Profile

Product Description

Mechanism Of Action

z-90099 - Drug Profile

Product Description

Mechanism Of Action

zotiraciclib citrate - Drug Profile

Product Description

Mechanism Of Action

Anaplastic Astrocytoma - Dormant Projects

Anaplastic Astrocytoma - Discontinued Products

Anaplastic Astrocytoma - Product Development Milestones

Featured News & Press Releases

Jan 19, 2022: Orbus Therapeutics' phase 3 Eflornithine STELLAR study reaches full patient enrollment

Sep 28, 2021: Orbus Therapeutics granted European patent for method of use for Eflornithine

Mar 02, 2021: Orbus Therapeutics announces positive outcome of pre-planned interim futility analysis for phase 3 Eflornithine STELLAR study

Dec 23, 2020: Orbus Therapeutics receives U.S. Patent for Eflornithine formulations

Jul 10, 2020: Geneos Therapeutics announces first patient dosed with its DNA-based, neoantigen-targeting personalized vaccine technology

Feb 04, 2020: STELLAR clinical trial of eflornithine to enrol brain tumour patients

May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019

Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer

Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anaplastic Astrocytoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Anaplastic Astrocytoma - Dormant Projects, 2022

Anaplastic Astrocytoma - Dormant Projects, 2022 (Contd..1)

Anaplastic Astrocytoma - Dormant Projects, 2022 (Contd..2)

Anaplastic Astrocytoma - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anaplastic Astrocytoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A5C462C387FCEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5C462C387FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

